Skip to main content
Erschienen in: Supportive Care in Cancer 6/2019

10.10.2018 | Original Article

The efficacy of oral piroxicam fast-dissolving tablets versus sublingual fentanyl in incident breakthrough pain due to bone metastases: a double-blinded randomized study

verfasst von: Ayman Abdalmaksoud Yousef, Ashraf Elsayed Alzeftawy

Erschienen in: Supportive Care in Cancer | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Breakthrough pain (BTP) is a transient exacerbation of pain occurring in a patient with chronic, persistent pain. The most common type is incident pain that is mostly related to bone metastases. The oral mucosa is an attractive route for drug delivery. Sublingual fentanyl preparations are a very attractive agent in controlling attacks of BTP due to its rapid absorption through the oral mucosa. Non-steroidal anti-inflammatory drugs (NSAIDs) play a key role as a first step in treatment of cancer pain; piroxicam sublingual formulations could be a useful alternative in controlling incident pain. Our study hypothesis is to evaluate the efficacy of sublingual fentanyl versus oral piroxicam fast-dissolving tablets in patients with incident pain and its impact on functional status.

Patients and methods

A cohort of 100 adults of both genders suffering from bone metastases. Patients were assigned to receive either sublingual fentanyl tablet (group 1) or oral piroxicam fast-dissolving tablets (group 2). The pain intensity reduction on a 0–10 visual analog scale (VAS), frequency of BTP attacks, and onset of pain relief. Secondary end points included the functional interference items of the Brief Pain Inventory (BPI).

Results

There is no significant difference between the two groups regarding the patients’ demographics. Significant decline of the VAS in each group in comparison to the pretreatment values (p = 0.001). Non-significant changes of the VAS, duration of pain attacks, and number of rescue doses in comparing both groups were measured. There was significant reduction in group 2 BPI regarding the relation with others, sleep pattern and enjoyment of life parameters at 2 and 4 weeks (p = 0.001).

Conclusion

Our study demonstrated that oral piroxicam fast-dissolving tablet is an analgesic alternative to sublingual fentanyl in patients with bone metastasis to control incidental BTP attacks with more favorable cost-benefit values.
Literatur
1.
Zurück zum Zitat Margarit C, Juliá J, López R, Anton A, Escobar Y, Casas A, Cruz JJ, Galvez R, Mañas A, Zaragozá F (2012) Breakthrough cancer pain– still a challenge. J Pain Res 5:559–566CrossRefPubMedPubMedCentral Margarit C, Juliá J, López R, Anton A, Escobar Y, Casas A, Cruz JJ, Galvez R, Mañas A, Zaragozá F (2012) Breakthrough cancer pain– still a challenge. J Pain Res 5:559–566CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Mishra S, Bhatnagar S, Chaudhary P, Pratap S, Rana S (2009) Breakthrough cancer pain: review of prevalence, characteristics and management. Indian Journal of Palliative Care 15(1):14–18CrossRefPubMedPubMedCentral Mishra S, Bhatnagar S, Chaudhary P, Pratap S, Rana S (2009) Breakthrough cancer pain: review of prevalence, characteristics and management. Indian Journal of Palliative Care 15(1):14–18CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Patel VF, Liu F, Brown MB (2011) Advances in oral transmucosal drug delivery. J Control Release 153:106–116CrossRefPubMed Patel VF, Liu F, Brown MB (2011) Advances in oral transmucosal drug delivery. J Control Release 153:106–116CrossRefPubMed
4.
Zurück zum Zitat Lennernäs B, Frank-Lissbrant I, Lennernäs H, Kälkner KM, Derrick R, Howell J (2010) Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain; results from a randomized phase II study. Palliat Med 24:286–293CrossRefPubMed Lennernäs B, Frank-Lissbrant I, Lennernäs H, Kälkner KM, Derrick R, Howell J (2010) Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain; results from a randomized phase II study. Palliat Med 24:286–293CrossRefPubMed
5.
Zurück zum Zitat Omoti AE, Omoti CE (2007) Pharmacological strategies for the management of cancer pain in developing countries. Pharm Pract 5(3):99–104 Omoti AE, Omoti CE (2007) Pharmacological strategies for the management of cancer pain in developing countries. Pharm Pract 5(3):99–104
6.
Zurück zum Zitat Kuo KL, Saokaew S, Stenehjem DD (2013) The pharmacoeconomics of breakthrough cancer pain. J Pain Palliat Care Pharmacother 27(2):167–175CrossRefPubMed Kuo KL, Saokaew S, Stenehjem DD (2013) The pharmacoeconomics of breakthrough cancer pain. J Pain Palliat Care Pharmacother 27(2):167–175CrossRefPubMed
7.
Zurück zum Zitat Mercadante S, Radbruch L, Caraceni A, Cherny N, Kaasa S, Nauck F, Ripamonti C, De Conno F (2002) Episodic (breakthrough) pain consensus conference of an expert working group of the European Association for Palliative Care. Cancer 94:832–839CrossRefPubMed Mercadante S, Radbruch L, Caraceni A, Cherny N, Kaasa S, Nauck F, Ripamonti C, De Conno F (2002) Episodic (breakthrough) pain consensus conference of an expert working group of the European Association for Palliative Care. Cancer 94:832–839CrossRefPubMed
8.
Zurück zum Zitat Mercadante S, Villari P, Ferrera P, Casuccio A (2004b) Optimization of opioid therapy for preventing incident pain associated with bone metastases. J Pain Symptom Manag 28:505–510CrossRef Mercadante S, Villari P, Ferrera P, Casuccio A (2004b) Optimization of opioid therapy for preventing incident pain associated with bone metastases. J Pain Symptom Manag 28:505–510CrossRef
9.
Zurück zum Zitat San K, Carla MB, Sheri LD, Jeff S, Tito RM, Charles SC (2004) Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 20(5):309–318CrossRef San K, Carla MB, Sheri LD, Jeff S, Tito RM, Charles SC (2004) Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 20(5):309–318CrossRef
10.
Zurück zum Zitat Zhang H, Zhang J, Streisand JB (2002) Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet 41:661–680CrossRef Zhang H, Zhang J, Streisand JB (2002) Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet 41:661–680CrossRef
11.
Zurück zum Zitat Payne R (1997) Mechanisms and management of bone pain. Cancer Supplement 80(8):1608–1613CrossRef Payne R (1997) Mechanisms and management of bone pain. Cancer Supplement 80(8):1608–1613CrossRef
12.
Zurück zum Zitat Yalcin S, Altundag K, Asil M, Tekuzman G (1998) Sublingual piroxicam for cancer pain. Med Oncol 15:137–139CrossRefPubMed Yalcin S, Altundag K, Asil M, Tekuzman G (1998) Sublingual piroxicam for cancer pain. Med Oncol 15:137–139CrossRefPubMed
13.
Zurück zum Zitat Gَmez-Batiste X, Madrid F, Moreno F, Gracia A, Trelis J, Nabal M et al (2002) Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manag 24:45–52CrossRef Gَmez-Batiste X, Madrid F, Moreno F, Gracia A, Trelis J, Nabal M et al (2002) Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manag 24:45–52CrossRef
14.
Zurück zum Zitat Davies AN, Vriens J, Kennett A, McTaggart M (2008) An observational study of oncology patients’ utilisation of breakthrough pain medication. J Pain Symptom Manag 35(4):406–411CrossRef Davies AN, Vriens J, Kennett A, McTaggart M (2008) An observational study of oncology patients’ utilisation of breakthrough pain medication. J Pain Symptom Manag 35(4):406–411CrossRef
15.
Zurück zum Zitat Janecki M, Janecka J (2011) Breakthrough pain in patients with chronic cancer pain followed by palliative care and pain clinic physicians — an observational study. Palliat Med 10(1):29–34 Janecki M, Janecka J (2011) Breakthrough pain in patients with chronic cancer pain followed by palliative care and pain clinic physicians — an observational study. Palliat Med 10(1):29–34
16.
Zurück zum Zitat Rauck RL, Tark M, Reyes E, Hayes TG, Bartkowiak AJ, Hassman D, Nalamachu S, Derrick R, Howell J (2009) Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin 25(12):2877–2885CrossRefPubMed Rauck RL, Tark M, Reyes E, Hayes TG, Bartkowiak AJ, Hassman D, Nalamachu S, Derrick R, Howell J (2009) Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin 25(12):2877–2885CrossRefPubMed
18.
Zurück zum Zitat Chwieduk CM, McKeage K (2010) Fentanyl sublingual: in breakthrough pain in opioid-tolerant adults with cancer. Drugs 70(17):2281–2288CrossRefPubMed Chwieduk CM, McKeage K (2010) Fentanyl sublingual: in breakthrough pain in opioid-tolerant adults with cancer. Drugs 70(17):2281–2288CrossRefPubMed
19.
Zurück zum Zitat Überall MA, Müller-Schwefe GH (2011) Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain. Curr Med Res Opin 27(7):1385–1394CrossRefPubMed Überall MA, Müller-Schwefe GH (2011) Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain. Curr Med Res Opin 27(7):1385–1394CrossRefPubMed
20.
Zurück zum Zitat Lister N, Warrington S, Boyce M, Eriksson C, Tamaoka M, Kilborn J (2011) Pharmacokinetics, safety, and tolerability of ascending doses of sublingual fentanyl, with and without naltrexone, in Japanese subjects. J Clin Pharmacol 51(8):1195–1204CrossRefPubMed Lister N, Warrington S, Boyce M, Eriksson C, Tamaoka M, Kilborn J (2011) Pharmacokinetics, safety, and tolerability of ascending doses of sublingual fentanyl, with and without naltrexone, in Japanese subjects. J Clin Pharmacol 51(8):1195–1204CrossRefPubMed
21.
Zurück zum Zitat Jandhyala R, Fullarton JR, Bennett MI (2013) Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. J Pain Symptom Manag 12:1–8 Jandhyala R, Fullarton JR, Bennett MI (2013) Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. J Pain Symptom Manag 12:1–8
22.
Zurück zum Zitat Shimoyama N, Gomyo I, Teramoto O, Kojima K, Higuchi H, Yukitoshi N, Ohta E, Shimoyama M (2015) Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain. Jpn J Clin Oncol 45(2):189–196CrossRefPubMed Shimoyama N, Gomyo I, Teramoto O, Kojima K, Higuchi H, Yukitoshi N, Ohta E, Shimoyama M (2015) Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain. Jpn J Clin Oncol 45(2):189–196CrossRefPubMed
23.
Zurück zum Zitat Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G (2009) The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 13:331–338CrossRefPubMed Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G (2009) The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 13:331–338CrossRefPubMed
Metadaten
Titel
The efficacy of oral piroxicam fast-dissolving tablets versus sublingual fentanyl in incident breakthrough pain due to bone metastases: a double-blinded randomized study
verfasst von
Ayman Abdalmaksoud Yousef
Ashraf Elsayed Alzeftawy
Publikationsdatum
10.10.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 6/2019
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-018-4469-6

Weitere Artikel der Ausgabe 6/2019

Supportive Care in Cancer 6/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.